Chronic HDV occurs only with HBV and confers markedly higher risks of rapid progression, cirrhosis, liver failure, and ...

Positioning shifts from treatment to prophylaxis, using vaccines to blunt antimicrobial resistance-driven unmet need and mitigate infection-associated long-term morbidity, including neurological ...

Talent and leadership culture convert finance into a strategic asset, emphasizing judgment under uncertainty and the ...

Reputation influences whether regulators, payers, clinicians, talent, and communities accelerate progress or impose friction, ...

Sales concentration follows a Pareto dynamic, but the exceptionally large eligible GLP-1 population inflates risk-adjusted ...

Harpreet Singh, MD, touches on how the Commissioner’s National Priority Voucher program is accelerating regulatory review timelines without fundamentally changing how pivotal trials are designed.

Kevin Dondarskit of Deloitte Consulting discusses the risks that drug makers face if they decide to put too much focus on an area where they may lack expertise, such as the emerging GLP-1 market. A ...

Makary’s departure followed internal disputes over approval decisions and Covid-19 vaccine posture, catalyzing a rapid ...

The Incyte–Genesis deal pairs significant upfront capital with long-tail milestones and royalties, while granting Incyte ...

Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall survival improved by five months in first-line metastatic TNBC. Objective ...

Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...